| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.1K | 8.0% | 7.2% |
| Total Income | 1.1K | 7.8% | 7.2% |
| Expenditure | 1.0K | 9.4% | 6.5% |
| PBT | 92.94 | 6.9% | 15.9% |
| Net Profit | 69.47 | 7.5% | 17.8% |
| OPM | 12.09% | 1.60pp | 10.65pp |
| NPM | 6.14% | 1.02pp | 0.55pp |
| EPS | 4.40 | 7.4% | 18.0% |
Jubilant Ingrevia Reports 18% Increase in Profit After Tax in Q2 FY26
27 Oct 2025 · 27 Oct 2025, 04:24 pm
Summary
Jubilant Ingrevia Ltd reported a 18% increase in Profit After Tax in Q2 FY26. The Speciality Chemicals segment drove the growth momentum with double digit YoY revenue growth. The Nutrition business maintained steady volume growth and the Chemical Intermediates business clocked highest quarterly sales. EBITDA grew by 8% year-over-year and Profit After Tax saw an impressive 18% increase. The company expects continued growth momentum in H2’FY26, fueled by progress in the Specialty Chemicals and Nutrition businesses.
Key Highlights
- 1
18% increase in Profit After Tax in Q2 FY26
- 2
Double digit YoY revenue growth in Speciality Chemicals segment
- 3
Steady volume growth in Nutrition business
- 4
Highest quarterly sales in Chemical Intermediates business
- 5
EBITDA grew by 8% year-over-year
- 6
Expected part-recovery in the Acetyls portfolio in H2’FY26
- 7
On track to start serving a major CDMO order in early 2026
Management Comments
Mr. Shyam S Bhartia
We are pleased to share the financial results for the second quarter of this fiscal year. Our Speciality Chemicals segment continues to drive the growth momentum with double digit YoY revenue growth and a positive growth over last quarter. Our Nutrition business maintained a steady volume growth trajectory across both the core products. Meanwhile, our Chemical Intermediates business clocked highest quarterly sales across value and volumes in last six quarters. Despite the challenging market conditions, we have grown revenues on the back of growth in volume-market-share and maintained profitability.
Informational and educational content only. Not investment advice.